Schering will have rights to "certain of Forest's patented oral, controlled release" drug delivery technology under terms of a license agreement announced by Forest on Feb. 6. The agreement presumably is for Forest's Synchron system, for which Forest's patent claim was recently confirmed by the U.S. Patent Office after a challenge from Merrell Dow.
You may also be interested in...
The (virtual) doors closing on the J.P. Morgan Healthcare Conference is the sign for the biopharma industry that the new year has truly started, but before we get too far into 2021, Scrip has taken a look at five of the biggest non-COVID-19 story themes of 2020 in no particular order.
Our graphic tracker of key developments from emergency authorized vaccines, the global roll-out, and late-stage vaccine candidates.
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.